使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning and welcome to Johnson & Johnson's first-quarter 2026 earnings conference call. (Operator Instructions) This call is being recorded. (Operator Instructions)
早安,歡迎參加強生公司(Johnson & Johnson)2026 年第一季財報電話會議。(接線員指示) 本通話將被錄音。(接線員指示)
I will now turn the call over to Johnson & Johnson. You may begin.
現在我將把電話交給強生公司。您可以開始。
Darren Snellgrove - Vice President - Investor Relations
Darren Snellgrove - Vice President - Investor Relations
Hello, everyone. This is Darren Snellgrove, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of business results for the first quarter of 2026, and our financial outlook for the full year.
各位好。我是強生公司投資人關係副總裁 Darren Snellgrove。歡迎參加我們對 2026 年第一季營運成果的回顧,以及對全年財務展望的說明。
First, a few logistics: as a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position, and business strategy.
首先,幾項會議安排提醒:今日簡報及相關附表可於強生公司網站的投資人關係專區 investor.jnj.com 取得。請注意,本簡報包含前瞻性陳述,內容涉及(但不限於)公司未來的營運與財務表現、市場地位及業務策略。
You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. The description of these risks, uncertainties and other factors can be found in our SEC filings, including our 2025 Form 10-K, which is available at investor.jnj.com and on the SEC's website.
敬請注意勿過度依賴這些前瞻性陳述;其係基於本錄音日期可得資訊、以對未來事件之目前預期為基礎,並受若干風險與不確定性影響,可能導致公司實際結果與所預測者出現重大差異。關於上述風險、不確定性及其他因素之說明,請參閱我們向美國證券交易委員會(SEC)提交的文件,包括 2025 年 Form 10-K;該文件可於 investor.jnj.com 及 SEC 網站查閱。
Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships.
此外,今日討論的若干產品與化合物係與策略夥伴合作開發,或自其他公司取得授權。本投影片用以致謝並說明上述合作關係。
Moving to today's agenda, Joaquin Duato, our Chairman and CEO, will discuss our business performance and growth drivers. I will then review the first-quarter sales and P&L results. Joe Wolk, our CFO, will then close by sharing an overview of our capital allocation priorities and updated guidance for 2026.
接著說明今日議程:我們的董事長兼執行長 Joaquin Duato 將討論公司營運表現與成長動能。隨後我將回顧第一季銷售與損益表(P&L)結果。最後,我們的財務長 Joe Wolk 將分享資本配置優先事項概覽,以及 2026 年最新財測指引。
Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine; John Reed, Executive Vice President, Innovative Medicine Research and Development; and Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will be joining us for Q&A. To ensure we provide enough time to address your questions, we anticipate the webcast will last approximately 60 minutes.
Jennifer Taubert(執行副總裁、全球創新醫藥事業主席)、John Reed(執行副總裁、創新醫藥研發)、以及 Tim Schmid(執行副總裁、全球醫療科技 MedTech 事業主席)將一同參與問答。為確保有足夠時間回覆各位提問,我們預期本次網路直播約為 60 分鐘。
With that, I will now turn the call over to Joaquin.
接下來,我把電話交給 Joaquin。
Joaquin Duato - Chairman of the Board, Chief Executive Officer
Joaquin Duato - Chairman of the Board, Chief Executive Officer
Good morning, everyone, and thank you for joining us. We said 2026 would be a year of accelerated growth and impact for Johnson & Johnson. And with our strong Q1 performance, including our beat on consensus and raised guidance, you can see we are delivering on that promise.
各位早安,感謝各位參與。我們曾表示 2026 年將是強生公司加速成長並擴大影響力的一年。而從我們第一季的強勁表現(包括優於市場一致預期以及上調財測指引)可以看出,我們正在兌現這項承諾。
In the first three months of the year, we delivered operational sales growth of 6.4%. Our focus on areas of high innovation, high unmet need, and high growth is delivering results today and for the future. Across each of our six key businesses: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision, we have multiple differentiated assets to drive sustained growth and a strong competitive advantage.
在今年前三個月,我們達成 6.4% 的營運銷售成長。我們聚焦於高創新、高未被滿足需求與高成長領域,正為當下與未來帶來成果。在我們六大關鍵業務——腫瘤、免疫、神經科學、心血管、外科與視力——我們擁有多項具差異化的資產,可推動持續成長並建立強勁競爭優勢。
Our success is fueled by the strongest portfolio and pipeline in the history of Johnson & Johnson. We currently have 28 platforms or products that generate at least $1 billion in annual revenue and we are aiming to add even more. Our unique combination of Innovative Medicine and MedTech, together with strong execution and industry-leading investment in innovation, is delivering resilient growth. We are on track to meet our 2026 target of $100 billion in annual revenue for the first time and we are confident our progress will continue to improve into 2027, with line of sight to double-digit growth by the end of the decade.
我們的成功來自強生公司史上最強的產品組合與研發管線。目前我們有 28 個平台或產品,每項年營收至少達 10 億美元,並致力於再增加更多。我們將創新醫藥(Innovative Medicine)與醫療科技(MedTech)獨特結合,再加上強勁執行力與業界領先的創新投資,正帶來具韌性的成長。我們正按計畫在 2026 年首次達成 1,000 億美元年營收目標,並有信心在 2027 年持續改善;同時也已可望在本十年末實現兩位數成長。
Let's start with Innovative Medicine where we delivered operational sales growth of 7.4% in the quarter with 10 brands growing double digits. In Oncology, we are aiming to cure and treat more cancers with the world's leading portfolio and pipeline.
先從創新醫藥事業開始,本季我們達成 7.4% 的營運銷售成長,且有 10 個品牌呈現兩位數成長。在腫瘤領域,我們以全球領先的產品組合與研發管線,致力於治癒並治療更多癌症。
DARZALEX remains the gold standard in multiple myeloma and our number-one product with sales of $4 billion and operational sales growth of 18%. CARVYKTI, TECVAYLI, and TALVEY also continue to deliver high double-digit growth reflecting the importance of our multiple myeloma portfolio across the full treatment journey. Progress in our pipeline accelerated in Q1 with the FDA approval of TECVAYLI plus DARZALEX FASPRO for relapsed or refractory multiple myeloma. That positions the regimen as a potential new standard of care as early as second line.
DARZALEX 仍是多發性骨髓瘤的黃金標準,也是我們銷售第一的產品,銷售額達 40 億美元,營運銷售成長 18%。CARVYKTI、TECVAYLI 與 TALVEY 亦持續繳出高雙位數成長,反映我們多發性骨髓瘤產品組合在完整治療旅程中的重要性。第一季我們的研發管線進展加速,FDA 核准 TECVAYLI 加上 DARZALEX FASPRO 用於復發或難治型多發性骨髓瘤。這使該療程有望最早自第二線治療起成為新的照護標準。
In solid tumors, RYBREVANT FASPRO received FDA approval for subcutaneous monthly dosing for patients with EGFR mutated non-small cell lung cancer. RYBREVANT also received FDA breakthrough therapy designation in advanced head and neck cancer with new data showing 56% overall response rate in first-line recurrent or metastatic head and neck cancer when combined with immunotherapy. The treatment is being further evaluated in the ongoing Phase 3 OrigAMI-5 study. And in high-risk non-muscle invasive bladder cancer, INLEXZO is outperforming all recent launches based on unique patients treated in the first 6 months post approval.
在實體腫瘤方面,RYBREVANT FASPRO 獲 FDA 核准可對 EGFR 突變之非小細胞肺癌患者採每月一次皮下注射給藥。RYBREVANT 亦在晚期頭頸癌獲 FDA 授予突破性療法認定;新數據顯示,於第一線復發或轉移性頭頸癌中,與免疫療法合併使用時整體反應率達 56%。該治療正於進行中的第三期 OrigAMI-5 研究中進一步評估。此外,在高風險非肌層浸潤性膀胱癌方面,INLEXZO 以核准後前 6 個月接受治療的獨特患者數衡量,表現優於近期所有新上市產品。
In Immunology, we continue to raise the bar in a category we have built for more than three decades from single innovations like REMICADE and STELARA to now a dual powerhouse of ICOTYDE and TREMFYA. TREMFYA had another very strong quarter with sales up 64%. It continues to be the fastest-growing IL-23 therapy in the U.S. and is now the share leader for new patient starts in inflammatory bowel disease. And with last month's FDA approval of ICOTYDE for the first-line treatment of plaque psoriasis, we are once again transforming the standard of care for immunology patients. ICOTYDE is the first and only IL-23 targeted oral peptide and has the potential to fundamentally change how psoriatic disease is treated by offering a convenient once-daily pill.
在免疫領域,我們持續提高標準;這是我們深耕逾三十年的領域,從 REMICADE 與 STELARA 等單一創新,發展到如今由 ICOTYDE 與 TREMFYA 組成的雙引擎主力。TREMFYA 本季再度表現強勁,銷售成長 64%。它仍是美國成長最快的 IL-23 療法,且目前在發炎性腸道疾病的新患者起始治療市占居首。隨著上月 FDA 核准 ICOTYDE 用於斑塊型乾癬第一線治療,我們再次改變免疫患者的照護標準。ICOTYDE 是首款且唯一鎖定 IL-23 的口服胜肽,具備以每日一次口服錠劑提供便利性的潛力,從根本改變乾癬性疾病的治療方式。
The full launch of ICOTYDE took place the same day as approval with the first patient receiving treatment that very day. While it is just the beginning, we're already seeing strong demand through our patient hub. Together, ICOTYDE and TREMFYA create a complementary category shaping portfolio. ICOTYDE is the first choice systemic treatment and TREMFYA is the first-choice biologic treatment for patients with moderate to severe plaque psoriasis.
ICOTYDE 在核准當天即全面上市,並於當日就有首位患者接受治療。雖然這只是開始,但我們已透過患者服務中心(patient hub)看到強勁需求。ICOTYDE 與 TREMFYA 共同構成一個互補、並可塑造品類格局的產品組合。對於中重度斑塊型乾癬患者,ICOTYDE 是首選的全身性治療,而 TREMFYA 則是首選的生物製劑治療。
ICOTYDE has the potential to be one of our largest products ever. TREMFYA is projected to deliver more than $10 billion in peak year sales. In neuroscience, we are focused on meaningfully improving outcomes in mental health. The US launch of CAPLYTA in adjunctive major depressive disorder is building momentum and SPRAVATO continues its strong growth trajectory.
ICOTYDE 有潛力成為我們史上最大的產品之一。預期 TREMFYA 在高峰年度的銷售額將超過 100 億美元。在神經科學領域,我們聚焦於在心理健康方面實質改善治療結果。CAPLYTA 於美國用於重度憂鬱症輔助治療的上市正持續累積動能,而 SPRAVATO 也延續其強勁的成長軌跡。
Now, let's turn to MedTech, where we reported Q1 operational sales growth of 4.6% with growth across all of our key focus areas. In Cardiovascular, we are investing in the growing need for complex interventions. Johnson & Johnson is the market leader in heart recovery, circulatory restoration, and electrophysiology, and we continue to deliver sustained growth. In heart recovery, Abiomed had another strong quarter as did Shockwave in circulatory restoration. And in electrophysiology, VARIPULSE our pulsed field ablation platform for atrial fibrillation keeps building momentum.
現在,讓我們把焦點轉向醫療科技(MedTech),我們公布第一季營運銷售成長4.6%,且在所有關鍵聚焦領域皆呈現成長。在心血管領域,我們正投資於日益增加的複雜介入治療需求。嬌生(Johnson & Johnson)在心臟復原、循環重建與電生理領域居於市場領導地位,並持續帶來穩健成長。在心臟復原方面,Abiomed 本季再度表現強勁;在循環重建方面,Shockwave 亦同樣表現亮眼。而在電生理方面,VARIPULSE——我們用於心房顫動的脈衝場消融(PFA)平台——持續累積動能。
Our confidence of continued leadership in electrophysiology was further strengthened by our recent launch of VARIPULSE Pro in Europe, with 5 times faster ablation, which helps streamline procedures and improve efficiency. As well as our recent VARIPURE 12 month data presented just a few days ago, we show a strong safety profile with zero reported strokes.
我們對於在電生理領域持續領先的信心,因近期在歐洲推出 VARIPULSE Pro 而進一步增強;其消融速度快5倍,有助於簡化手術流程並提升效率。此外,就在幾天前公布的 VARIPURE 12個月數據顯示,我們具備強勁的安全性表現,且未報告任何中風事件。
We also continue to receive strong feedback in Europe for our Dual Energy THERMOCOOL SMARTTOUCH SF Catheter, which we expect to launch in the US later this year, having recently submitted a complete platform to FDA. And finally, we recently announced 12-month data for OMNYPULSE, our large focal-tip PFA catheter, showing positive outcomes, no safety events, and 100% procedural success rate.
我們也持續在歐洲收到對雙能量 THERMOCOOL SMARTTOUCH SF 導管的正面回饋;我們預期將於今年稍晚在美國上市,並已於近期向 FDA 提交完整平台資料。最後,我們近期公布 OMNYPULSE(我們的大型焦點尖端 PFA 導管)12個月數據,顯示結果正向、無安全事件,且手術成功率達100%。
In Surgery, our strong performance reflects the deep levels of trust and our expanding presence in the operating room. In Q1, we made progress on our OTTAVA robotic surgical system, and we are building on our recent De Novo filing for approval with a second Investigational Device Exemption trial now underway for inguinal hernia repair.
在外科領域,我們的強勁表現反映出深厚的信任基礎,以及我們在手術室內持續擴大的布局。第一季,我們在 OTTAVA 機器人手術系統方面取得進展;在近期以 De Novo 途徑提交審查以取得核准的基礎上,我們也啟動了第二項「研究用醫療器材豁免」(IDE)試驗,針對腹股溝疝氣修補。
In Vision, we are restoring sight to its healthiest state with expanding access globally for our ACUVUE OASYS MAX disposable lenses for presbyopia and astigmatism and our TECNIS intraocular lenses. Most significantly, we received FDA approval of TECNIS PURESEE, the first and only extended-depth-of-focus intraocular lens in the US to maintain contract sensitivity comparable to a monofocal lens. 97% of patients reported no very bothersome visual disturbances like halos or glare.
在視力保健領域,我們透過在全球擴大 ACUVUE OASYS MAX 老花與散光日拋隱形眼鏡,以及 TECNIS 人工水晶體的可及性,協助恢復視力至最健康狀態。最重要的是,我們獲得 FDA 核准 TECNIS PURESEE——這是美國首款且唯一的延伸景深(EDOF)人工水晶體,能維持與單焦點鏡片相當的對比敏感度。97%的患者表示沒有非常困擾的視覺干擾,例如光暈或眩光。
As you can see, we are off to a fast start in 2026, building momentum that will accelerate our impact and growth throughout the year and for the balance of the decade. The depth of our portfolio and pipeline has never been stronger, and I'm confident we'll continue to deliver on our commitments for 2026 and beyond.
如各位所見,我們在2026年開局迅速,並持續累積動能,將在今年以及本十年剩餘期間加速擴大我們的影響力與成長。我們的產品組合與研發管線深度前所未有地強勁,我有信心我們將持續兌現對2026年及未來的承諾。
And with that, I will turn the call back over to Darren.
接下來,我把電話會議交回給 Darren。
Darren Snellgrove - Vice President - Investor Relations
Darren Snellgrove - Vice President - Investor Relations
Thank you, Joaquin. Moving to our financial results, unless otherwise stated, the percentages quoted represent operational results and therefore, exclude the impact of currency translation. Starting with Q1 2026 sales results, worldwide sales were $24.1 billion for the quarter. Sales increased 6.4% despite an approximate 540 basis point headwind from STELARA. Excluding STELARA, Johnson & Johnson grew double digits for the quarter. Growth in the US was 8.3% and 3.9% outside of the US. Acquisitions and divestitures had a net positive impact on worldwide growth of 110 basis points primarily driven by the Intra-Cellular acquisition.
謝謝你,Joaquin。接著說明我們的財務結果;除非另有說明,所引用的百分比皆為營運結果,因此不包含匯率換算影響。先從2026年第一季銷售結果開始,本季全球銷售額為241億美元。儘管 STELARA 帶來約540個基點的不利影響,銷售仍成長6.4%。若排除 STELARA,嬌生本季呈現雙位數成長。美國成長8.3%,美國以外地區成長3.9%。併購與資產處分對全球成長的淨影響為正向110個基點,主要由 Intra-Cellular 併購所帶動。
Now, turning to earnings, for the quarter, net earnings were $5.2 billion and diluted earnings per share were $2.14 versus $4.54 a year ago. Adjusted net earnings for the quarter were $6.6 billion, and adjusted diluted earnings per share were $2.70, representing a decrease of 1.4% and 2.5%, respectively, compared to the first quarter of 2025.
接著談獲利,本季淨利為52億美元,稀釋後每股盈餘為2.14美元,去年同期為4.54美元。本季調整後淨利為66億美元,調整後稀釋每股盈餘為2.70美元,較2025年第一季分別下降1.4%與2.5%。
I will now comment on business sales performance in the quarter focusing on the six key areas where meaningful innovation is driving our performance and fueling long-term growth, beginning with Innovative Medicine where our financial results reflect the depth of our expertise and innovation in areas of high unmet need across Oncology, Immunology and Neuroscience.
接下來我將就本季各事業的銷售表現進行說明,聚焦於六個由重大創新驅動、帶動我們表現並支撐長期成長的關鍵領域;首先是創新醫藥(Innovative Medicine),我們的財務結果反映出在腫瘤、免疫與神經科學等高未滿足需求領域的專業深度與創新能力。
Worldwide sales of $15.4 billion increased 7.4% despite an approximate 920 basis point headwind from STELARA, which underscores the continued strength of our key brands and new launches. Growth in the US was 9.6% and 4.3% outside of the US. Acquisitions and divestitures had a net positive impact of 180 basis points on worldwide growth primarily due to the Intra-Cellular acquisition.
全球銷售額154億美元成長7.4%,儘管 STELARA 帶來約920個基點的不利影響,仍凸顯我們核心品牌與新上市產品的持續強勁表現。美國成長9.6%,美國以外地區成長4.3%。併購與資產處分對全球成長的淨正向影響為180個基點,主要來自 Intra-Cellular 併購。
In Oncology, starting with multiple myeloma, DARZALEX growth was 17.8%, primarily driven by strong share gains of 5.9 points across all lines of therapy with nearly 12 points in the frontline setting as well as market growth. CARVYKTI achieved sales of approximately $600 million with growth of 57.4%, driven by share gains and continued site expansion.
在腫瘤領域,先從多發性骨髓瘤開始,DARZALEX 成長17.8%,主要由各治療線別合計提升5.9個百分點的強勁市占增長所帶動,其中在一線治療情境接近提升12個百分點,並受惠於市場成長。CARVYKTI 銷售額約6億美元,成長57.4%,主要由市占提升與持續擴增治療據點所驅動。
TECVAYLI growth was 30.1% with sequential growth of 14.2%, driven by launch uptake and share gains from expansion in the community setting as well as the US approval of TECVAYLI plus DARZALEX FASPRO. TALVEY growth was 72.8%, driven by share gains through expansion in the community setting.
TECVAYLI 成長30.1%,季比成長14.2%,主要由上市導入、在社區醫療場域擴張帶來的市占提升,以及美國核准 TECVAYLI 搭配 DARZALEX FASPRO 所帶動。TALVEY 成長72.8%,主要由在社區醫療場域擴張所帶來的市占提升所驅動。
In Lung Cancer, RYBREVANT plus LAZCLUZE delivered sales of $257 million and growth of 80.5%, driven by continued launch uptake in all regions, share gains and rapid uptake in RYBREVANT FASPRO. Share gains in both the first and second lines continue to drive strong sequential growth of 18.8%.
在肺癌方面,RYBREVANT 搭配 LAZCLUZE 銷售額為2.57億美元,成長80.5%,主要由各地區持續的上市導入、市占提升,以及 RYBREVANT FASPRO 的快速採用所帶動。第一線與第二線治療的市占提升持續推動強勁的季比成長18.8%。
In Prostate Cancer, ERLEADA delivered strong growth of 16.2% due to continued share gains and market growth. Within Immunology, TREMFYA delivered impressive growth of 63.8%. Our IBD launch is driving significant momentum, and we continue to see share gains across all indications as well as market growth. STELARA declined 61.7% driven by share loss due to biosimilar competition, increasing adoption of novel classes and unfavorable patient mix.
在前列腺癌方面,ERLEADA 受惠於持續的市占提升與市場成長,繳出16.2%的強勁成長。在免疫領域,TREMFYA 交出亮眼的63.8%成長。我們的 IBD 上市推動顯著動能,我們持續看到各適應症的市占提升以及市場成長。STELARA 下滑61.7%,主要由生物相似藥競爭導致的市占流失、新型藥物類別採用增加,以及不利的病患組合所致。
In Neuroscience, SPRAVATO grew 44.5% driven by continued strong demand from physicians and patients. CAPLYTA, which was acquired in Q2 of 2025 as part of the Intra-Cellular acquisition, delivered sales of $270 million for the quarter, with continued strong momentum in our aMDD launch. Since aMDD approval in the US, CAPLYTA has had its highest ever new patient start volumes across all indications.
在神經科學方面,SPRAVATO 成長44.5%,主要由醫師與病患持續強勁的需求所帶動。CAPLYTA 於2025年第二季隨 Intra-Cellular 併購取得,本季銷售額為2.70億美元,且我們在 aMDD 上市方面持續展現強勁動能。自 CAPLYTA 在美國取得 aMDD 核准以來,其在所有適應症的新病患起始用藥量創下歷史新高。
Now moving to MedTech, where we delivered growth across each of our key focus areas, Cardiovascular, Surgery, and Vision. Worldwide sales of $8.6 billion increased 4.6%, with growth of 5.9% in the US and 3.2% outside of the US. Divestitures had a net negative impact of 10 basis points on worldwide growth.
接著回到醫療科技(MedTech),我們在各關鍵聚焦領域——心血管、外科與視力保健——皆實現成長。全球銷售額86億美元成長4.6%,其中美國成長5.9%,美國以外地區成長3.2%。資產處分對全球成長的淨影響為負向10個基點。
In Cardiovascular, electrophysiology delivered growth of 9.5%, driven by our newly launched products, including VARIPULSE and commercial execution. Abiomed delivered growth of 14.4%, with continued strong adoption of the Impella technology. Shockwave delivered strong double-digit growth of 18.1% driven by continued adoption of coronary and peripheral products.
在心血管領域,電生理業務成長9.5%,主要由我們新近上市的產品(包括VARIPULSE)以及商業執行所帶動。Abiomed成長14.4%,Impella技術持續強勁導入。Shockwave在冠狀動脈與周邊產品持續導入的帶動下,實現18.1%的強勁雙位數成長。
Surgery grew 1.2% despite a negative impact of approximately 30 basis points from divestitures. Growth was driven by strength of the portfolio and commercial execution in biosurgery and wound closure, partially offset by planned surgery transformation impacts and competitive pressures in energy and endocutters, as well as VBP in China across the portfolio.
外科業務成長1.2%,儘管剝離資產帶來約30個基點的負面影響。成長主要由生物外科與傷口閉合領域的產品組合優勢與商業執行力所驅動,但部分被既定的外科轉型影響、能量平台與內視鏡切割縫合器(endocutters)的競爭壓力,以及中國全產品組合範圍內的VBP所抵銷。
In Vision, contact lenses and other products grew 2.7%, driven by strong performance in the ACUVUE OASYS 1-Day family of products, as well as strategic price actions, further solidifying our leadership position. Surgical Vision grew 6%, driven by new product innovations, robust demand for premium IOLs and strong commercial execution, partially offset by competitive pressures in the US. Orthopaedics growth this quarter was 3.2%, primarily driven by new product launches and strong commercial execution.
在視力保健領域,隱形眼鏡及其他產品成長2.7%,主要由ACUVUE OASYS 1-Day系列產品的強勁表現,以及策略性價格措施所帶動,進一步鞏固我們的領導地位。視覺外科成長6%,由新產品創新、高階人工水晶體(IOL)的強勁需求與優異的商業執行所驅動,但部分被美國市場的競爭壓力所抵銷。本季骨科業務成長3.2%,主要由新產品上市與強勁的商業執行所帶動。
Now, turning to our consolidated statement of earnings for the first quarter of 2026. I'd like to highlight a few noteworthy items that have changed compared to the same quarter of last year. Cost of goods sold deleveraged by 10 basis points, driven by the impact of tariffs and other operational drivers in the MedTech business, an unfavorable mix in the Innovative Medicine business. This was partially offset by favorable translational currency in the Innovative Medicine business.
接下來,讓我們看2026年第一季的合併損益表。我想強調幾個相較去年同期有所變動的重點項目。銷貨成本去槓桿10個基點,主要受MedTech業務關稅影響及其他營運因素,以及創新醫藥業務不利的產品組合所致。上述影響部分被創新醫藥業務有利的換算匯率所抵銷。
Selling, marketing, and administrative expense deleveraged by 180 basis points, driven by heavier investment in new launches early in the year and increased investment related to the acquisition of Intra-Cellular in the Innovative Medicine business. Research and development remained flat at 14.7% of sales. Interest income and expense was a net expense of $43 million as compared to $128 million of income in the first quarter of 2025. The decrease in income was driven by a lower average cash balance and a higher average debt balance. Other income and expense was a net expense of $294 million as compared to $7.3 billion of income in the first quarter of 2025, with the change primarily driven by the approximate $7 billion talc reserve reversal in the first quarter of 2025.
銷售、行銷及管理費用去槓桿180個基點,主要因年初對新產品上市加大投資,以及創新醫藥業務與收購Intra-Cellular相關的投資增加。研發費用占銷售比重維持不變,為14.7%。利息收入及費用淨額為費用4,300萬美元,相較於2025年第一季為收入1.28億美元。收入下降主要由平均現金餘額較低及平均負債餘額較高所致。其他收入及費用淨額為費用2.94億美元,相較於2025年第一季為收入73億美元;變動主要由2025年第一季約70億美元的滑石粉(talc)準備金回轉所驅動。
Tax rate on a GAAP basis in the first quarter of 2026 was 12.6% compared to 19.3% in the first quarter of 2025. This was primarily driven by the reversal of the talc settlement accrual in the first quarter of 2025, which did not reoccur and discrete tax benefits associated with employee equity programs in the first quarter of 2026. Lastly, I'll direct your attention to the box section of the slide, where we have also provided our income before tax, net earnings, and earnings per share adjusted to exclude the impact of intangible amortization expense and special items.
2026年第一季按GAAP基礎計算的稅率為12.6%,相較於2025年第一季的19.3%。這主要是因2025年第一季滑石粉和解應計負債回轉未再發生,以及2026年第一季與員工股權計畫相關的一次性稅務利益。最後,請注意投影片的方框區塊,我們亦提供了剔除無形資產攤銷費用及特殊項目影響後調整的稅前利益、淨利與每股盈餘。
Now, let's look at adjusted income before tax by segment for the quarter. Innovative Medicine margin declined from 42.5% to 39.7%, primarily driven by heavier investment in new launches early in the year. Unfavorable product mix and certain favorable one-time items recorded in 2025, partially offset by favorable translational currency.
現在,讓我們看看本季按事業部門劃分的調整後稅前利益。創新醫藥的利潤率由42.5%下降至39.7%,主要因年初對新產品上市的投資加重。不利的產品組合,以及2025年入帳的某些一次性有利項目;部分被有利的換算匯率所抵銷。
MedTech margin declined from 25.9% to 22.3% primarily driven by the impact of tariffs in cost of products sold and certain favorable one-time items recorded in 2025. As a result, adjusted income before tax for the enterprise as a percentage of sales decreased from 36.6% to 32.5%.
MedTech利潤率由25.9%下降至22.3%,主要因銷貨成本中關稅的影響,以及2025年入帳的某些一次性有利項目。因此,企業層級的調整後稅前利益占銷售比重由36.6%下降至32.5%。
This concludes the sales and earnings portion of the call, and I will now turn the call over to Joe.
以上為本次電話會議的銷售與獲利部分,接下來我將把電話會議交給Joe。
Joseph Wolk - Chief Financial Officer, Executive Vice President
Joseph Wolk - Chief Financial Officer, Executive Vice President
Thanks, Darren. Hello, everyone. We appreciate you joining us today. As Joaquin noted, we are seeing good momentum across our business, powered by our industry-leading portfolio, sustained investment in innovation, and disciplined execution. We continue to advance our pipeline by bringing innovative new treatments to patients, which will meaningfully improve patient outcomes and fortify future performance, giving us a clear line of sight to double-digit growth by the end of the decade.
謝謝你,Darren。各位好。感謝各位今天加入我們。如Joaquin所提到的,我們看到各項業務均有良好動能,這得益於我們業界領先的產品組合、對創新的持續投資,以及嚴謹的執行。我們持續推進研發管線,將創新的新療法帶給病患,這將顯著改善病患治療結果並強化未來表現,使我們能清楚看見在本十年末實現雙位數成長的路徑。
Turning to cash and capital allocation, we ended the first quarter with approximately $22 billion of cash and marketable securities and $55 billion of debt for a net debt of approximately $33 billion. Free cash flow in the first quarter was approximately $1.5 billion. Clearly, this suggests a run rate below our full-year projection as Q1 reflects payment timing changes on certain US rebate programs and increased US capital expenditures. However, these were expected, and we remain confident in our full-year free cash flow outlook of approximately $21 billion.
談到現金與資本配置,我們在第一季末持有約220億美元的現金及有價證券,負債為550億美元,淨負債約330億美元。第一季自由現金流約為15億美元。顯然,這顯示的運行水準低於我們全年預測,因為第一季反映了美國部分回扣計畫付款時點的變動,以及美國資本支出增加。不過,這些皆在預期之內,我們仍對全年約210億美元的自由現金流展望保持信心。
Our strong financial position and cash flow generation provides a competitive advantage, enabling us to maintain a consistent approach to capital allocation and investment in future innovation. Since announcing our plans to invest $55 billion in US-based manufacturing technology and research and development through early 2029, we are well on our way to reaching that target. Through the end of 2025, we invested roughly $12 billion or 22% of the $55 billion with significant investment already underway in 2026.
我們強健的財務狀況與現金流創造能力帶來競爭優勢,使我們能維持一致的資本配置方針,並投資於未來創新。自我們宣布計畫在2029年初之前投資550億美元於美國本土製造技術及研發以來,我們正穩步朝該目標邁進。截至2025年底,我們已投資約120億美元,約占550億美元的22%,且2026年已有大量投資正在進行。
Our manufacturing investments include facilities in North Carolina and Pennsylvania, and we will have more announcements to come in upcoming quarters. Lastly, we recognize our shareholders value a growing dividend. Today, we were pleased to announce the Board of Directors' authorization for a 3.1% increase to an annual rate of $5.36 per share, our 64th consecutive year of dividend growth. Turning now to full year 2026 guidance. We are increasing our operational sales guidance to be in the range of 5.9% to 6.9%, with a midpoint of $100.2 billion or 6.4%.
我們的製造投資包括北卡羅來納州與賓夕法尼亞州的設施,未來幾季我們也將有更多公告。最後,我們了解股東重視持續成長的股利。今天,我們很高興宣布董事會已核准將年度股利提高3.1%,至每股年化5.36美元,這是我們連續第64年股利成長。接下來談2026年全年指引。我們將營運銷售成長指引上調至5.9%至6.9%的區間,中位數為1,002億美元或6.4%。
As noted last quarter, our financial calendar in 2026 includes a 53rd week, which provides a benefit of approximately 100 basis points. We do not speculate on future currency movements and last quarter, we utilized the euro spot rate relative to the US dollar of $1.17. As of last week, the euro spot rate to the US dollar has stayed relatively flat, with modest benefit from other major currencies. As a result, we estimate reported sales growth between 6.5% to 7.5% with a midpoint of $100.8 billion or 7%.
如上季所述,我們2026年的財務年度包含第53週,帶來約100個基點的助益。我們不對未來匯率變動進行推測;上季我們採用歐元兌美元1.17的即期匯率。至上週為止,歐元兌美元即期匯率大致持平,其他主要貨幣帶來小幅助益。因此,我們估計報告口徑的銷售成長介於6.5%至7.5%,中位數為1,008億美元或7%。
Turning to other notable items on the P&L, we are maintaining our guidance for adjusted pretax operating margin to improve by at least 50 basis points in 2026. This will be driven by continued operating efficiencies with a portion reinvested to support new product launches and further strengthen the pipeline. As today's Q1 results reflect, heavier investment is planned to occur in the first half of the year.
再看損益表上的其他重點項目,我們維持2026年調整後稅前營業利潤率至少提升50個基點的指引。這將由持續的營運效率提升所驅動,其中一部分將再投資以支持新產品上市並進一步強化研發管線。如今日第一季結果所反映,較重的投資規劃將發生在上半年。
As a reminder, our pretax operating margin guidance takes into account the costs from the 53rd week of operations and the announced voluntary agreement with the US government to improve access to medicines and lower cost to US patients. We are maintaining our guidance for net interest expense, net other income and the effective tax rate for the full year.
提醒一下,我們對稅前營業利益率的指引已納入第53週營運所產生的成本,以及我們先前宣布與美國政府達成的自願協議之相關成本,該協議旨在改善藥品可近性並降低美國病患的用藥負擔。我們維持全年淨利息費用、其他淨收益以及有效稅率的指引不變。
Turning to adjusted operational earnings per share, we are increasing our guidance by $0.02 to a range of $11.30 to $11.50, representing 5.7% growth at the midpoint. As such, we now expect reported adjusted earnings per share of $11.55 at the midpoint or a growth of 7.1%.
接著談調整後營運每股盈餘,我們將指引上調0.02美元至11.30至11.50美元區間,以中點計算代表成長5.7%。因此,我們目前預期申報的調整後每股盈餘中點為11.55美元,或成長7.1%。
I'll now shift to some qualitative considerations on phasing for your models. As noted last quarter, we anticipate fairly consistent operational sales growth throughout the year with a higher fourth quarter due to the benefit from the 53rd week referenced earlier. In Innovative Medicine, the depth and strength of our portfolio will continue to drive accelerating growth this year. We expect contributions from our newly launched products across Oncology, Immunology, and Neuroscience to increase throughout the year.
接下來我將就各位模型中的分期(phasing)提供一些質性考量。如同上季所提,我們預期全年營運銷售成長將相當一致,而第四季會較高,主要受先前提到的第53週效益帶動。在創新醫藥(Innovative Medicine)方面,我們產品組合的深度與強度將持續推動今年成長加速。我們預期今年新上市產品在腫瘤、免疫與神經科學領域的貢獻將隨時間逐步增加。
As Joaquin mentioned, we are excited by the launch of ICOTYDE as well as that of INLEXZO, our innovative new therapy for certain types of bladder cancer, which had sales slightly above $30 million in the quarter. On April 1, we received a permanent J-code for INLEXZO reimbursement, which will enable broader patient access and serve as an important catalyst for growth.
如Joaquin所提,我們對ICOTYDE的上市以及INLEXZO的上市都感到振奮;INLEXZO是我們針對特定膀胱癌類型的創新新療法,本季銷售略高於3,000萬美元。4月1日,我們取得INLEXZO給付用的永久J-code,這將使更多病患得以使用,並成為成長的重要催化劑。
In Neuroscience, CAPLYTA continued to build momentum following its FDA approval in adjunctive major depressive disorder with new patient starts and total continuing patient growth outpacing the market. We believe this performance supports CAPLYTA's peak annual sales potential of greater than $5 billion, and we look forward to sharing additional data in bipolar mania later this year.
在神經科學方面,CAPLYTA在獲得FDA核准用於重度憂鬱症的輔助治療後持續累積動能,新病患起始用藥與持續用藥病患總數的成長均超越市場。我們相信這樣的表現支持CAPLYTA年峰值銷售額超過50億美元的潛力,並期待在今年稍晚分享其在雙相躁症(bipolar mania)方面的更多數據。
In MedTech, our focus this year is on accelerating the adoption of our recently launched products. ETHICON 4000, our next-generation surgical stapler launched in the US in 2025 and is expected to launch in Europe shortly. In Vision, we continue to expand the TECNIS platform globally and look forward to the US launch of TECNIS PureSee intraocular lens, which enables surgeons to address cataract-related vision loss and presbyopia in a single procedure.
在醫療科技(MedTech)方面,我們今年的重點是加速近期上市產品的採用。ETHICON 4000是我們新一代外科縫合釘合器,已於2025年在美國上市,並預期不久後在歐洲上市。在視力(Vision)領域,我們持續在全球擴展TECNIS平台,並期待TECNIS PureSee人工水晶體在美國上市,該產品可讓外科醫師在單一手術中同時處理白內障相關視力損失與老花。
In electrophysiology, VARIPULSE Pro is an innovative step forward, introducing a new faster pulse sequence that reduces ablation time by 85%. We do anticipate some second half impact from volume-based procurement in China for electrophysiology products, which has been factored into our full-year guidance.
在電生理方面,VARIPULSE Pro是一項創新性的重大進展,導入新的更快速脈衝序列,可將消融時間縮短85%。我們確實預期中國針對電生理產品的以量採購將在下半年帶來一些影響,且此影響已反映在我們的全年指引中。
The Orthopaedics business under the leadership of Namal Nawana, delivered a strong first quarter with encouraging momentum across key platforms. We are continuing to make targeted investments in the business and working towards a mid-2027 separation. We look forward to sharing further updates later this year. And as stated last October, we are evaluating all separation vehicles that create shareholder value and set up the DePuy Synthes business for long-term success.
在Namal Nawana的領導下,骨科(Orthopaedics)業務第一季表現強勁,主要平台均展現令人鼓舞的動能。我們持續對該業務進行有針對性的投資,並朝著於2027年年中分拆的目標推進。我們期待在今年稍晚分享更多最新進展。此外,如同去年10月所述,我們正在評估所有能創造股東價值、並為DePuy Synthes業務奠定長期成功基礎的分拆方式。
Turning to our pipeline, we have many important catalysts that we are looking forward to in 2026. In Innovative Medicine, we expect regulatory approval for TREMFYA for the inhibition of structural joint damage for patients with psoriatic arthritis. As this chart indicates, we also have many important upcoming data presentations across Oncology, Immunology, and Neuroscience, including ERLEADA in localized and locally advanced high-risk prostate cancer, INLEXZO in high-risk non-muscle invasive bladder cancer; JNJ-4804 in ulcerative colitis and Crohn's disease; and CAPLYTA in bipolar mania. In MedTech, we anticipate the following approvals and regulatory submissions: OTTAVA Robotic Surgical System, VARIPULSE Pro in the US, ETHIZIA in biosurgery, and the Dual Energy THERMOCOOL SMARTTOUCH SF catheter in the US.
接著談我們的研發管線,2026年我們有許多重要的催化劑值得期待。在創新醫藥方面,我們預期TREMFYA將獲得監管核准,用於抑制乾癬性關節炎患者的結構性關節損傷。如圖表所示,我們在腫瘤、免疫與神經科學領域也有多項即將發表的重要數據,包括:ERLEADA用於局部及局部晚期高風險前列腺癌、INLEXZO用於高風險非肌層浸潤性膀胱癌;JNJ-4804用於潰瘍性結腸炎與克隆氏症;以及CAPLYTA用於雙相躁症。在醫療科技方面,我們預期將有以下核准與法規送件:OTTAVA機器人手術系統、VARIPULSE Pro在美國、用於生物外科(biosurgery)的ETHIZIA,以及Dual Energy THERMOCOOL SMARTTOUCH SF導管在美國。
Before we move to Q&A, we'd like to thank our colleagues around the world for delivering another solid quarter. Their execution continues to optimize our portfolio, advance our pipeline, and deliver on our mission of improving and saving lives. Our diversified portfolio, robust pipeline, and strong financial foundation position us to drive accelerating and sustainable growth while creating near- and long-term value for shareholders.
在進入問答之前,我們想感謝全球同仁再度交出穩健的一季成績。他們的執行力持續優化我們的產品組合、推進研發管線,並實現我們改善並拯救生命的使命。我們多元化的產品組合、強健的研發管線與穩固的財務基礎,使我們得以推動加速且可持續的成長,同時為股東創造近期與長期價值。
Speaking of long term, we look forward to providing an in-depth look at our long-term strategy and the driving forces behind our path to double-digit growth. Please mark your calendars for December 8, the date of our Enterprise Business Review.
談到長期,我們期待更深入地說明我們的長期策略,以及推動我們邁向雙位數成長路徑背後的驅動因素。請在行事曆上標記12月8日,這一天是我們的企業業務回顧(Enterprise Business Review)。
With that, we are happy to take your questions. Kevin, can you please open the call for Q&A.
接下來,我們很樂意回答各位的問題。Kevin,麻煩你開放電話進入問答環節。
Operator
Operator
(Operator Instructions) Terence Flynn, Morgan Stanley.
(接線員指示) Morgan Stanley的Terence Flynn。
Terence Flynn - Analyst
Terence Flynn - Analyst
Great, thanks for taking the question and congrats on all the progress. I had a two-part one on ICOTYDE. I was just wondering if you can remind us of how you're positioning that drug in the market now that we have full details on the label and pricing? And also, how should we think about the ramp of reimbursement coverage there and any sampling plans?
太好了,謝謝讓我提問,也恭喜你們取得各項進展。我有一個關於ICOTYDE的兩段式問題。想請你們提醒一下,在我們已掌握完整標籤與定價細節之後,你們目前如何在市場上定位這個藥?另外,我們應該如何看待其給付覆蓋的爬坡速度,以及是否有任何試用(sampling)計畫?
Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals
Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals
Thanks. Well, good morning, Terence. Hello, everyone. And I just wanted to start with a big thanks to the entire Innovative Medicine team throughout the world, really strong results in the first quarter with over $15 billion in net sales 7.4% operational growth. Really importantly, 10 key brands delivering double-digit growth. And if you take a look at what is now 96% of our business that is not including STELARA, we actually grew at 16.6%, so really nice accelerating growth across the portfolio.
謝謝。Terence,早安。各位好。我想先向全球創新醫藥團隊致上衷心感謝;第一季表現非常強勁,淨銷售額超過150億美元,營運成長7.4%。更重要的是,有10個關鍵品牌實現雙位數成長。如果你看目前占我們業務96%、不包含STELARA的部分,實際上成長達16.6%,因此整體產品組合呈現非常好的加速成長。
So I'm thrilled to talk about ICOTYDE, really one of our outstanding products. And I've got to tell you it's off to a very fast start. The product was approved back in March. And we're really, really happy with what we believe is a very differentiated label for the product as the first and only targeted oral peptide that precisely blocks the IL-23 receptor.
所以我很高興談談ICOTYDE,這確實是我們非常出色的產品之一。我必須說,它的起步非常快。該產品在3月獲得核准。我們對其標籤的高度差異化感到非常、非常滿意;它是第一個也是唯一一個可精準阻斷IL-23受體的標靶口服胜肽。
ICOTYDE, maybe as a reminder, delivers complete skin clearance, favorable safety and the simplicity of a once-daily pill, and we think it's got the potential to become one of our biggest products. So we were day one launch ready for the product. And in fact, first patient was actually on medication within 24 hours of approval. We're seeing very strong early enthusiasm from both physicians and patients that reinforce our confidence in the potential for this product. A number of us were out at the AAD meeting as well.
再提醒一下,ICOTYDE可達到皮膚完全清除、具良好安全性,且每日一次口服的用藥方式相當簡便;我們認為它有潛力成為我們最大的產品之一。因此,我們在上市第一天就已準備就緒。事實上,第一位病患在核准後24小時內就已開始用藥。我們看到醫師與病患在早期就展現非常強烈的熱忱,進一步強化我們對此產品潛力的信心。我們當中也有不少人參加了AAD年會。
And the KOL receptivity to the strength and the simplicity of the label has been really encouraging things like no lab monitoring, the TB language that reflects the physician clinical judgment, no black box or drug interactions, really is giving us good confidence that this is going to be really the preferred choice and first choice for systemic therapy.
而KOL(關鍵意見領袖)對於標籤內容的力度與簡潔性的接受度,確實令人非常鼓舞;例如不需要實驗室監測、反映醫師臨床判斷的TB用語、沒有黑框警語或藥物交互作用等,這些都讓我們更有信心,這將會成為全身性治療中真正的首選與偏好選擇。
In terms of early uptake, we're seeing so far about 1,500 patients already that prescriptions have been written for that are going into access and patient support service center, so already 1,500 and already over 1,000 unique customers that are writing. In terms of payers, our goal is to have both early and broad access. And we're in the middle of very, very positive conversations with them to try to drive that early and very broad access, so more to come on that.
就早期採用而言,截至目前我們已看到約1,500名患者已開立處方,並正在進入給付取得與患者支持服務中心流程,因此已經有1,500名患者,且已有超過1,000位不重複客戶在開立處方。就支付方而言,我們的目標是同時達成早期且廣泛的可及性。我們正與他們進行非常、非常正面的對話,以推動早期且非常廣泛的可及性,後續會再分享更多進展。
In terms of the positioning, I can't think of a better portfolio than being able to have both ICOTYDE and TREMFYA for our folks and really for patients, so with ICOTYDE being the first and only targeted oral peptide is really going to become the preferred first-line systemic therapy. We know there are so many patients that keep cycling and cycling on topical therapies.
就產品定位而言,我想不出有比同時擁有ICOTYDE與TREMFYA更好的產品組合,無論是對我們的團隊,還是真正對患者而言;ICOTYDE作為首個且唯一的標靶口服胜肽,確實將成為偏好的第一線全身性治療。我們知道有非常多患者一直在外用治療上反覆輪替、周而復始。
Now, the International Psoriasis Foundation guidelines have changed so that patients after two topicals and trials of four weeks each really become eligible for systemic and advanced therapies. And so we think ICOTYDE fits right in this sweet spot as that first choice systemic.
目前,國際乾癬基金會的指引已經改變:患者在使用兩種外用藥、且每種試用四週後,就真正符合接受全身性與進階治療的資格。因此我們認為,ICOTYDE正好契合這個「甜蜜點」,成為第一選擇的全身性治療。
Likewise, TREMFYA holds a really unique and distinct position as well. And that really is the first choice biologic. And so TREMFYA is both structurally and functionally different from the other IL-23s. We've been able to demonstrate really durable complete skin clearance and in our case here, it's the first and only IL-23 that's got significant inhibition of structural damage.
同樣地,TREMFYA也擁有非常獨特且明確的定位。它確實是首選的生物製劑。TREMFYA在結構與功能上都不同於其他IL-23產品。我們已能證明其具備非常持久的完全皮膚清除效果;而在我們這裡,它是首個且唯一在結構性損傷抑制方面具有顯著效果的IL-23。
So we think it's really the first choice biologic, especially in patients that have active or suspected PSA or psoriatic arthritis. So we think that with that one, two punch, we have got the portfolio for psoriatic disease in patients and are really excited about both agents going forward.
因此我們認為它確實是首選的生物製劑,特別適用於有活動性或疑似PSA(乾癬性關節炎)的患者。所以我們認為,憑藉這一記「組合拳」,我們已擁有面向乾癬性疾病患者的產品組合,並對兩項藥物未來的發展都感到非常振奮。
John Reed - Executive Vice President - Pharmaceuticals, R&D
John Reed - Executive Vice President - Pharmaceuticals, R&D
Maybe I would just add one other thing, John Reed here, our study of ICOTYDE in psoriatic arthritis should read out later this year. That's important given that about a third of patients with psoriasis also develop psoriatic arthritis. And the studies in inflammatory bowel diseases, Crohn's and colitis are off and rolling that Phase 3 program.
我也許再補充一點,我是John Reed;我們針對ICOTYDE在乾癬性關節炎的研究,應會在今年稍晚讀出結果。這點很重要,因為約三分之一的乾癬患者也會發展為乾癬性關節炎。而在發炎性腸道疾病方面,克隆氏症與結腸炎的研究也已啟動並推進該第3期計畫。
Operator
Operator
Larry Biegelsen, Wells Fargo.
Larry Biegelsen,富國銀行。
Lawrence Biegelsen - Analyst
Lawrence Biegelsen - Analyst
Good morning. Thanks for taking the question and congrats on a nice start to the year here. Tim, sentiment in the medical device space is relatively low right now because of a number of headwinds and concerns. You posted a respectable growth rate this quarter, but it was slightly below the Q4 growth rate and the comp in Q1 was relatively easy. So my question is, what are you seeing in your end markets? And how are you thinking about the remainder of the year?
早安。謝謝讓我提問,也恭喜今年開局表現不錯。Tim,目前醫療器材領域的市場情緒相對低迷,因為存在多項逆風與疑慮。你們本季繳出可觀的成長率,但略低於第4季的成長率,而且第1季的比較基期相對容易。所以我的問題是:你們在終端市場看到了什麼?以及你們如何看待今年剩餘期間的走勢?
Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech
Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech
Let me jump right in and say that, as you know, we've been very clear, Larry, in articulating our strategy, which is focused on higher growth and higher innovation markets, and that includes our deliberate choice to prioritize our three focus areas of Cardiovascular, Vision, and Surgery as we separate Ortho. And I can confidently say that, that strategy is working.
我先直接回應:如你所知,Larry,我們一直非常清楚地闡述我們的策略,也就是聚焦於更高成長、更多創新的市場;這也包括在我們分拆骨科(Ortho)的同時,有意識地選擇優先投入三大重點領域:心血管、視力與外科。我可以很有信心地說,這個策略正在奏效。
And in short, while we're navigating a dynamic world and market like everybody else for us, Q1 unfolded as we expected the year to start seasonally quieter but operationally solid, and this was also not a one business or one region quarter, as you've seen by the results, we saw growth across the board. And overall, we're pleased with the 4.6% operational growth, especially given that Q1 is typically our most seasonally subdued quarter.
簡而言之,雖然我們和大家一樣都在應對一個動態的世界與市場,但對我們而言,第1季的發展符合預期:年度開局在季節性上較為清淡,但營運表現穩健;而且這也不是單一事業或單一地區支撐的一季,從結果你也看得到,我們各方面都出現成長。整體而言,我們對4.6%的營運成長感到滿意,尤其考量到第1季通常是我們季節性最淡的一季。
And I think it's also worth noting, Larry, that while there were some easier year-over-year comparisons this by no means drove the quarter. Specifically, the 210 basis points of onetime impact we referenced in Q1 of last year, which you will recall was a bit of a noisy quarter were almost entirely related to the items that occurred in 2024. And so those prior year events temporarily depressed the year-over-year growth rate, creating a lighter comparator but they did not affect on the underlying dollar sales. And so one-time items from 2024 fully lapped last year, and our Q1 performance reflects underlying operational execution and normal seasonality rather than any benefit from prior one-timers.
另外我也認為值得一提的是,Larry,雖然確實存在一些較容易的年對年比較,但這絕非推動本季表現的主因。具體而言,我們提到去年第1季有210個基點的一次性影響;你會記得那是一個相對雜訊較多的季度,而這些幾乎完全與2024年發生的事項相關。因此,前一年度事件暫時壓低了年對年成長率,造成較輕的比較基期,但並未影響底層的美元銷售額。所以,2024年的一次性因素在今年已完全消除(lapped),我們第1季的表現反映的是底層營運執行與正常季節性,而非受益於前期的一次性因素。
So I'd say in summary, Larry, overall, Q1 played out largely as we anticipated, balancing normal seasonality with solid execution. And most importantly, nothing in the quarter changes our confidence in further acceleration as we look towards Q2 and the remainder of 2026.
因此總結來說,Larry,第1季的表現大致如我們所預期,在正常季節性與穩健執行之間取得平衡。更重要的是,本季沒有任何情況會改變我們對於在展望第2季及2026年剩餘期間進一步加速成長的信心。
And we've got a lot of growth catalysts to be proud of. What I will say in terms of the underlying market is that it's solid and underlying demand is what we expected. Now, we did see some procedural softness early in the quarter, but nothing that we would define really as material while certain regions, particularly here in the US, you will recall, we experienced some periods of severe weather in late January and early February. That was largely consistent with normal seasonal patterns and while there was some localized impact on procedure volumes due to poor weather in parts of the business, we would not categorize them as material or meaningful at an overall level.
而我們也有許多值得自豪的成長催化劑。就底層市場而言,我要說的是市場狀況穩健,底層需求也符合我們的預期。確實,我們在本季初看到部分手術量略有疲軟,但沒有任何我們會認定為實質性的影響;在某些地區,特別是美國,你會記得我們在1月下旬與2月上旬經歷了一些嚴重天氣時段。這大致符合正常的季節性型態;雖然惡劣天氣在部分業務上對手術量造成局部影響,但就整體層面而言,我們不會將其歸類為重大或有意義的影響。
And so what I'm proud of is our teams are highly experienced in managing these types of short-term disruptions and our supply chain, our clinical support and commercial teams work closely with healthcare providers to maintain continuity of service and support patient care. And so in short, Larry, a strong quarter for us, consistent with our expectations, and we believe strongly in the robustness of our end markets. Thank you.
因此我感到自豪的是,我們的團隊在管理這類短期干擾方面經驗非常豐富;我們的供應鏈、臨床支援與商業團隊也與醫療服務提供者緊密合作,以維持服務連續性並支持患者照護。所以簡而言之,Larry,對我們而言這是一個強勁的季度,符合我們的預期;我們也堅信終端市場具有韌性。謝謝。
Operator
Operator
Asad Haider, Goldman Sachs.
Asad Haider,高盛。
Asad Haider - Analyst
Asad Haider - Analyst
Great. Congrats on yet another solid quarter. For Joaquin, just going back to the goal of double-digit top line growth towards the end of the decade, that's still not something that's getting reflected in consensus models. And in light of your comment earlier that ICOTYDE could be one of your largest products ever, that would suggest an opportunity of at least $10 billion. So any updated views on what you see as the key product variances versus the Street looking towards the end of the decade? And related, how important is the BD lever in that growth algorithm?
很好。恭喜又交出一個穩健的季度。想請教Joaquin,回到你們在本十年末實現營收雙位數成長的目標,這在市場一致預估模型中仍未被反映。再加上你先前提到ICOTYDE可能成為你們史上最大的產品之一,這暗示至少有100億美元的機會。因此,對於你們認為在本十年末、相較於華爾街預期的關鍵產品差異(variances),是否有任何更新看法?以及相關地,BD(業務發展)這個槓桿在該成長方程式中有多重要?
Joaquin Duato - Chairman of the Board, Chief Executive Officer
Joaquin Duato - Chairman of the Board, Chief Executive Officer
Thank you very much. And look, again, as you can see, we are off to a fast start with momentum that will accelerate throughout the year in 2027. And as you mentioned, with line of sight to double-digit growth by the end of the decade. And I think it's a fair question. How is that possible for a company that this year in 2026 is going to deliver more than $100 billion.
非常感謝。你看,如你所見,我們以快速的步伐開局,且這股動能將在2027年全年持續加速。正如你提到的,我們也能清楚看到在本十年末達成雙位數成長的路徑。我認為這是個合理的問題。對於一家在2026年將交付超過1,000億美元營收的公司而言,這怎麼可能?
This is grounded in reality, as a matter of fact, it's already happening today. If you look at the first quarter of 2026, we are already delivering double-digit growth as total Johnson & Johnson when you exclude the STELARA. So it's already happening today. And it's based on our portfolio and pipeline, the strongest in our history.
這是立基於現實的;事實上,今天就已經在發生。如果你看2026年第一季,在排除STELARA之後,我們整體強生(Johnson & Johnson)已經實現兩位數成長。所以這在今天就已經在發生。而這是基於我們的產品組合與研發管線,為我們史上最強。
And also, as the decade progresses we are going to see increasing impact in our revenue of our new product launches that are largely derisked. In particular, as you mentioned, there's still an underestimation of the potential of ICOTYDE, in psoriatic arthritis and IBD, the potential of RYBREVANT in non-small cell lung cancer, head and neck, where we got breakthrough designation and colorectal cancer and finally, the potential of INLEXZO in high-risk non-muscle invasive bladder cancer.
此外,隨著十年進程推進,我們將看到已大幅去風險的新產品上市,對營收帶來愈來愈大的影響。特別是如你所提到的,市場仍低估了ICOTYDE在乾癬性關節炎與IBD的潛力、RYBREVANT在非小細胞肺癌以及頭頸癌(我們已取得突破性療法認定)與大腸直腸癌的潛力,最後還有INLEXZO在高風險非肌層浸潤性膀胱癌的潛力。
By the way, INLEXZO got the J-code earlier in April. So I believe those are three particular products that remain underestimated that are already marketed. The same is true in MedTech where launches, especially in Cardiovascular, including our next-generation PFA catheters and Impella ECP, along with OTTAVA in robotic surgery are not yet fully reflected as well as the fact that the separation of Orthopaedics will further lift our growth rates. So I think you -- when you take into consideration all those factors, you are going to get into a similar conclusion of double-digit growth by the end of the decade.
順帶一提,INLEXZO在4月初就已取得J-code。因此我相信,這三項已上市的產品仍被特別低估。MedTech也是如此,尤其是心血管領域的上市產品,包括我們的次世代PFA導管與Impella ECP,再加上機器人手術的OTTAVA,這些尚未被充分反映;此外,骨科業務的分拆也將進一步拉升我們的成長率。所以我認為——當你把所有這些因素納入考量,你會得出相近的結論:到本十年末將達到兩位數成長。
Further, I would say that the strong sales growth will also drive operating leverage that will be further amplified when the US. DARZALEX royalties roll off in 2029. So taken together, this creates what some of you have called the cleanest growth story in healthcare. And we are going to be providing additional details in our Enterprise Business Review that will take place in December as we have announced today. Regarding BD, let me be clear, all these numbers do not include business development. This is based in the strong portfolio pipeline that we have today that is largely derisked, which increases the confidence in our ability to get there.
另外我會說,強勁的銷售成長也將帶動營運槓桿,而在美國DARZALEX權利金於2029年到期(停止)後,這種效果將進一步放大。綜合而言,這形成了你們其中一些人所稱的醫療保健領域最「乾淨」的成長故事。而正如我們今天所宣布的,我們將在12月舉行的企業業務回顧(Enterprise Business Review)中提供更多細節。關於BD(業務發展),我想說清楚:所有這些數字都不包含業務發展。這是基於我們目前強勁且已大幅去風險的產品組合與研發管線,這也提升了我們達成目標的信心。
When it comes to business development, I mean, that remains an important part of our capital allocation. As a matter of fact, I would say we have been ahead of the curve in our investments in M&A with the acquisitions during the last 2.5 years of Abiomed, Shockwave, and Intra-Cellular.
談到業務發展,我的意思是,這仍是我們資本配置的重要一環。事實上,我會說我們在併購投資上一直走在前面,過去2.5年完成了對Abiomed、Shockwave與Intra-Cellular的收購。
As I have commented in multiple times, our sweet spot remains early-stage deals like the one we did earlier this year with Halda Therapeutics, which brings a new platform in our Oncology business. And at the same, I have to say that given the situation that I just described, our priority from a capital allocation perspective, our priority is to invest behind our portfolio of new product launches and our promising pipeline programs. So that's our priority today.
正如我多次提到的,我們的甜蜜點仍是早期階段的交易,例如我們今年稍早與Halda Therapeutics所做的交易,為我們的腫瘤業務帶來一個新平台。同時我也必須說,鑑於我剛才描述的情況,從資本配置角度來看,我們的優先事項是加大投資於新產品上市的產品組合,以及具前景的研發管線專案。所以這是我們目前的優先事項。
We remain opportunistic from a business development standpoint but we do not depend on M&A to be able to deliver on that promise. So in summary, we see both revenue growth and operating margins improving and we reaffirm that we have line of sight to double-digit growth by the end of the decade.
在業務發展方面我們仍會把握機會,但我們不依賴併購來兌現這項承諾。因此總結來說,我們看到營收成長與營業利潤率都在改善,我們也重申:到本十年末,我們對兩位數成長有清晰可見的路徑(line of sight)。
Operator
Operator
Chris Schott, JPMorgan.
Chris Schott,摩根大通(JPMorgan)。
Christopher Schott - Analyst
Christopher Schott - Analyst
Congrats on the progress. I just had a two-parter coming back to ICOTYDE. Maybe the first one, you mentioned 1,500 prescriptions so far. Is there any color on where those customers are coming from as we think about new patients versus those switching off orals versus those switching off injectables? And then just on the bigger picture view of ICOTYDE, as you mentioned, potential for the drug to become one of the company's largest ever. The pathway to get there, should we think about this as a similar dynamic to TREMFYA that skews more towards IBD versus psoriasis or is this one that could have more balanced sales by indication given, as you mentioned, the frontline potential of the drug in the psoriasis setting?
恭喜你們的進展。我有兩個問題想回到ICOTYDE。第一個,你提到目前約有1,500張處方。就我們思考新病患與從口服藥轉換、或從注射劑轉換的情況而言,能否分享一下這些客戶主要來自哪裡?第二個是從更宏觀的角度看ICOTYDE,如你所說,這款藥有潛力成為公司史上最大的產品之一。要走到那一步的路徑,我們應該把它視為類似TREMFYA那種更偏向IBD而非乾癬的動態,還是說考量到你提到該藥在乾癬一線治療的潛力,它在各適應症之間可能會有更均衡的銷售結構?
Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals
Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals
Chris, thanks so much for the question. So in terms of the early information on ICOTYDE. Obviously, it is really early. So we're still getting information and I can tell you that there's a broad range of prescribers for ICOTYDE as we look across the medical community. We don't yet have data that is specific to exactly where that's coming from, what is exactly new, what they're switching off of, et cetera.
Chris,非常感謝你的提問。就ICOTYDE的早期資訊而言,顯然現在還非常早期。所以我們仍在蒐集資訊;我可以告訴你的是,從整個醫療社群來看,ICOTYDE的開立醫師涵蓋範圍很廣。我們目前還沒有足夠具體的數據,能精確說明處方來源、哪些是新病患、他們是從哪些療法轉換而來等等。
So hopefully, we'll have greater granularity on that at our next call, next quarter. So obviously, it's pretty new and hot off the press. I think as we take a look at ICOTYDE, ICOTYDE is going to fit in psoriasis really firmly in that systemic first-line therapy area. And that is also a great opportunity there for market expansion. If you think there are so many patients that are cycling on topicals, they are resistant to moving into biologics for a number of reasons, whether it's needle phobia, perceptions around safety profile and things.
希望在下一次電話會議、也就是下個季度,我們能提供更細的資訊。所以很明顯,這還很新,消息也才剛出爐。我認為就乾癬而言,ICOTYDE會非常穩固地定位在全身性一線治療(systemic first-line therapy)這個區塊。而這也帶來很好的市場擴張機會。如果你想想,有非常多病患一直在外用藥之間反覆更換,他們因為各種原因不願意進入生物製劑治療,無論是害怕打針、對安全性特徵的觀感等等。
We think not only given the size of the current systemic market and having significant impact there, but really being able to expand that broader is going to be key for ICOTYDE's success. I also think when you think about IBD and having an oral agent, we've got to see the studies pan out. But based on our goals there, we think that, that's going to be a similar very, very large opportunity. I think here, we're going to see maybe more of a balanced scenario given the strength that we really anticipate having in psoriasis, but I think both segments, both psoriatic disease and inflammatory bowel diseases are going to be very big offer a lot of potential and promise for ICOTYDE.
我們認為,ICOTYDE不僅能在現有全身性治療市場中產生重大影響,更重要的是能把市場擴大,這將是ICOTYDE成功的關鍵。我也認為,當你想到IBD並擁有一個口服藥物,我們還需要看研究結果如何發展。但基於我們在那裡的目標,我們認為那也會是同樣非常、非常大的機會。我想在這裡,考量到我們預期在乾癬領域會有很強的表現,銷售結構可能會更均衡;但我認為兩個領域——乾癬相關疾病與發炎性腸道疾病——都會非常大,為ICOTYDE帶來大量潛力與前景。
John Reed - Executive Vice President - Pharmaceuticals, R&D
John Reed - Executive Vice President - Pharmaceuticals, R&D
Yes, Chris, maybe just one other comment on that is that across most autoimmune diseases, about 70% to 80% of patients who are eligible for our biologics are not taking one. And so that's why we really think about this market expansion opportunity to offer patients the convenience of a highly effective very safe once a day pill.
是的,Chris,另外補充一點:在多數自體免疫疾病中,大約有70%到80%符合使用我們生物製劑資格的病患並未使用生物製劑。因此我們才會非常看重這個市場擴張機會,為病患提供一種便利、療效很高、且非常安全的每日一次口服藥。
Operator
Operator
Shagun Singh, RBC Capital Markets.
Shagun Singh,RBC資本市場(RBC Capital Markets)。
Shagun Singh - Analyst
Shagun Singh - Analyst
I wanted to touch on some of your growth drivers within the Medical Device business. Abiomed post-ACC, some of our checks are suggesting that within the high-risk population, we could see up to a 30% reduction. How does that compare with your expectation? And it looks like the IDL space is looking to get increasingly more competitive. So how do you manage your market leadership position in that space? And then overall, as I think about all the drivers that you mentioned within medical devices, should we think about MedTech as a high single-digit growth contributor towards the double-digit growth that you've called out for total company by the end of the decade?
我想談談你們在醫療器材業務中的一些成長驅動因素。Abiomed在ACC之後,我們的一些查核顯示,在高風險族群中,我們可能會看到最高達30%的降低幅度。這與你們的預期相比如何?另外,看起來IDL領域正變得愈來愈競爭。你們如何在該領域維持市場領導地位?最後,整體而言,當我把你提到的所有醫療器材驅動因素納入考量時,我們是否應將MedTech視為到本十年末、你所提出的公司整體兩位數成長目標中的一個「高個位數」成長貢獻者?
Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech
Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech
Shagun, thank you for the question. And there's a lot in there. Let me try and unpack it. Firstly, we are really excited to be now significantly embedded in the cardiovascular space beyond the leadership position we hold in electrophysiology and with the acquisitions of both Abiomed and Shockwave, we've added to high-growth, high-margin businesses with tremendous trajectory for the future. Abiomed, as you know, grew 14%, almost 15% in the first quarter, and this is really driven by rapid adoption of Impella 5.5 and CP and what excites me most going forward is Abiomed's robust pipeline of not only technologies, but ongoing clinical studies showing the benefits of this technology.
Shagun,謝謝你的提問。裡面涵蓋了很多內容。我試著把它拆解說明。首先,我們非常興奮,因為除了我們在心臟電生理領域所擁有的領導地位之外,我們現在也已大幅深入心血管領域;透過收購 Abiomed 與 Shockwave,我們新增了具高成長、高毛利、且未來發展軌跡極為可觀的業務。如你所知,Abiomed 第一季成長 14%,接近 15%,主要是由 Impella 5.5 與 CP 的快速採用所帶動;而更令我對未來感到振奮的是,Abiomed 強勁的產品線不僅包含多項技術,還有持續進行的臨床研究,顯示這項技術的效益。
And you will know that in August of last year, we saw a new data from the DanGer Shock randomized controlled trial published in the New England Journal of Medicine, and this really confirmed the long-term survival benefit of Impella. These results found that up to 10 years when compared to the standard of care, routine use of Impella in patients who had a STEMI heart attack with cardiogenic shock lead to an absolute mortality reduction of 16.3%.
你也會知道,去年 8 月,我們看到 DanGer Shock 隨機對照試驗的新數據發表於《新英格蘭醫學期刊》,這確實證實了 Impella 的長期存活效益。結果顯示,與標準治療相比,在長達 10 年的追蹤中,對於發生 STEMI 心肌梗塞且合併心因性休克的患者,常規使用 Impella 可帶來 16.3% 的絕對死亡率降低。
And to put this in context, when compared with the control arm of 10 years, Impella CP patients gained an average of 600 additional days alive. I mean, that is compelling. And so while you're always going to see new data and new studies come about, we believe that our evidence base for the products we have and the indications we have today are absolutely solid and will continue to drive performance in a category where we don't have line of sight to any significant competitor for the foreseeable future.
為了讓大家更有感,與 10 年追蹤的對照組相比,Impella CP 患者平均多存活了 600 天。我的意思是,這非常有說服力。因此,雖然你總會看到新的數據與新的研究出現,但我們相信,就我們目前的產品與現有適應症而言,我們的證據基礎非常扎實,並將持續推動表現;而在可預見的未來,我們也看不到任何具重大威脅的競爭對手。
I'll turn to Shockwave, 18.1% in the first quarter, and we're very pleased with that performance. The IVL market is one we completely have created ourselves through the acquisition of Shockwave and we continue to advance our leadership position. Now clearly, competition is coming. Competition is going to come to any space that is attractive and certainly one as attractive as IVL. But there's 3 reasons that we have confidence in our portfolio and our future.
再談 Shockwave,第一季成長 18.1%,我們對這樣的表現非常滿意。IVL 市場是我們透過收購 Shockwave 親手打造出來的市場,我們也持續強化我們的領導地位。當然,競爭正在到來。任何有吸引力的領域都會出現競爭者,而 IVL 無疑是非常有吸引力的領域。但我們有三個理由對我們的產品組合與未來充滿信心。
And the first thing really is our portfolio. The second is evidence, and it's our presence. And over the past 7 years, we've had -- we've earned the reputation of an innovative disruptor, launching 9 -- yes, 9 new coronary and peripheral catheters that have introduced a new standard of care when it comes to safely and effectively treating calcified lesions. And as a result, Shockwave IVL has become the preferred treatment strategy in most calcium cases worldwide where it has been used in now more than 1 million cases around the world, and global expansion has also increased since the acquisition as we had transitioned 10 markets to direct sales forces.
第一是我們的產品組合。第二是證據,第三是我們的市場佈局與觸及。在過去 7 年,我們——我們建立了創新顛覆者的聲譽,推出了 9 款——沒錯,9 款新的冠狀動脈與周邊血管導管,為安全且有效治療鈣化病灶引入了新的照護標準。因此,Shockwave IVL 已成為全球多數鈣化病例的首選治療策略;迄今在全球已使用超過 100 萬例。自收購以來,隨著我們將 10 個市場轉為直營銷售團隊,全球擴張也進一步加速。
We've expanded our presence to now cover 17 markets globally with J&J representatives where we can leverage our scale and the broader J&J organization to drive government relations and address any legal and market access opportunities. And while we will never take any competitor for granted, new competitive entrants into the IVL market, validate really Shockwave's robust portfolio in leading specific solutions.
我們已將佈局擴展至全球 17 個市場,由 J&J 業務代表覆蓋;我們可以運用規模與更廣泛的 J&J 組織來推動政府關係,並掌握任何法規與市場准入的機會。而且,雖然我們從不低估任何競爭者,但 IVL 市場的新進入者,某種程度上也驗證了 Shockwave 強健的產品組合與領先的特定解決方案。
And while competitors are introducing some of the versions to our first-generation products from 2017, we're introducing our fifth generation coronary peripheral devices in 2026 and a single catheter offering will be difficult to compete against Shockwave's portfolio strategy and the improvements we've made over the years to reset the standard of IVL.
當競爭者還在推出一些相當於我們 2017 年第一代產品的版本時,我們預計在 2026 年推出第五代冠狀動脈與周邊血管裝置;而僅靠單一導管的產品供應,很難與 Shockwave 的產品組合策略,以及我們多年來為重新定義 IVL 標準所做的改良相抗衡。
And while new competitors are completing their first regulatory required clinical studies, we're continuing to invest millions in robust real-world clinical evidence with nearly 25,000 patient outcomes published across 600 journals to date, demonstrating our unique safety profile exclusively associated with Shockwave's ultrasonic acoustic platform and what physicians also appreciate is our compact easy-to-use and rechargeable generators, which require minimal capital expenditure. And back to the point of presence, these generators provide widespread access to Shockwave's IVL technology and they're available in almost every cath lab across the United States, and we actually have more than two generators in over 1,700 US hospitals, and so very difficult for competitors to unseat us.
當新的競爭者還在完成其法規要求的第一批臨床研究時,我們持續投入數百萬美元建立強健的真實世界臨床證據;截至目前,已在 600 本期刊發表近 25,000 名患者的結局數據,展現我們獨特的安全性特徵——這是 Shockwave 超音波聲學平台所獨有的。醫師也很欣賞我們小巧、易用且可充電的產生器,所需資本支出極低。回到「佈局與觸及」這點,這些產生器讓 Shockwave 的 IVL 技術得以廣泛可及,幾乎在美國每一間導管室都能取得;而且在美國超過 1,700 家醫院中,我們實際上配置了兩台以上的產生器,因此競爭者要撼動我們非常困難。
Most importantly, I'd say is we remain hyper-focused on continuing to earn our innovative disruptor reputation with plans to launch at least one new IVL catheter per year that we expect will redefine the future of IVL in new indications and new disease states. And this year, we will launch our C2 Aero new coronary catheter, which from the early feedback we've got from physicians is going to be another standout product. I think to your final point around long-term prospects. We're excited about our growth profile and the catalysts we have to continue to accelerate MedTech from a mid-single-digit player into a higher single-digit player as we move towards the end of the decade. I will point to some big catalysts, especially in our surgery business.
最重要的是,我們仍高度聚焦於持續贏得「創新顛覆者」的聲譽,計畫每年至少推出一款新的 IVL 導管;我們預期這將在新的適應症與新的疾病領域中,重新定義 IVL 的未來。今年我們將推出 C2 Aero 新款冠狀動脈導管,從目前醫師的早期回饋來看,這會是另一個非常突出的產品。至於你最後提到的長期前景。我們對成長輪廓以及能持續加速 MedTech 的催化劑感到振奮,目標是在本十年末,將我們從「中個位數成長」推進到「較高個位數成長」。我會特別指出一些重要催化劑,尤其是在我們的外科業務。
Surgery is one of our larger portfolios. We are a dominant leader, both in the open and laparoscopic space. And we have an expectation to play a big role in the robotics space. As you know, we've submitted OTTAVA for approval. And assuming everything plays out, we expect that by the end of this year, we will be launching not one but two new surgical robotic programs, both with OTTAVA and MONARCH for urology.
外科是我們較大的產品組合之一。無論在開放式手術或腹腔鏡領域,我們都是主導性的領導者。而且我們預期在手術機器人領域扮演重要角色。如你所知,我們已提交 OTTAVA 申請核准。若一切按計畫推進,我們預期在今年底前,將不只推出一個、而是兩個新的手術機器人計畫,分別是 OTTAVA,以及用於泌尿科的 MONARCH。
Now, what we don't expect those programs to be significantly accretive to growth in the short term, they certainly will be accretive as we move to the back half of the decade. So another good example of an important catalyst that will take us from a mid-single-digit player into a higher single-digit player as we look to the back half of the decade.
我們不預期這些計畫在短期內會對成長有顯著增益,但在本十年後半段,它們肯定會帶來增益。因此,這也是另一個重要催化劑的例子,將在本十年後半段把我們從中個位數成長推進到較高個位數成長。
Operator
Operator
Alexandria Hammond, Wolfe Research.
Alexandria Hammond,Wolfe Research。
Alexandria Hammond - Equity Analyst
Alexandria Hammond - Equity Analyst
A few more on ICOTYDE. Can you walk us through the investments you guys are making on prescriber and patient education? And how important do you think advertising will be to kind of engage those new patients who might be nervous to start on a systemic therapy? And then just as a follow-up as well, with ICONIC-ASCEND trial set to read out imminently, how important could this result be those ongoing commercial discussions?
再多問幾個關於 ICOTYDE 的問題。你們能否說明一下在處方醫師與患者教育方面所做的投資?你認為廣告在吸引那些可能對開始全身性治療感到緊張的新患者方面,有多重要?另外再追問一下,ICONIC-ASCEND 試驗即將公布結果,這個結果對目前正在進行的商業討論可能有多重要?
John Reed - Executive Vice President - Pharmaceuticals, R&D
John Reed - Executive Vice President - Pharmaceuticals, R&D
The study ADVANCE, in the head-to-head against the TYK2 inhibitor is, I think, just illustrates the best-in-disease profile for ICOTYDE in terms of having both that high-level efficacy combined with safety in the once-a-day pill. How much the direct-to-consumer is going to matter, I'm going to let Jennifer answer that question.
ADVANCE 研究在與 TYK2 抑制劑的頭對頭比較中,我認為清楚展現了 ICOTYDE 的「同類最佳」特徵:在每日一次口服藥的形式下,同時具備高水準療效與安全性。至於直接面向消費者(DTC)的推廣會有多重要,我讓 Jennifer 來回答這個問題。
Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals
Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals
Alex, it's safe to say that we are investing big in ICOTYDE to make sure that this brand can do all that it can do for patients. I think that the ease and the simplicity when you combine the clinical profile, the safety, the efficacy and then the ease of the product, we really believe that we've got a winner. And so we're investing to really get off to a very strong launch, that's with all of the appropriate field teams.
Alex,可以很肯定地說,我們正在大力投資 ICOTYDE,以確保這個品牌能為患者發揮它所能發揮的一切價值。我認為,當你把臨床特徵、安全性、療效,再加上產品使用的便利與簡單性結合起來,我們真的相信我們手上有一個贏家。因此,我們正在投入資源,確保能以非常強勁的態勢啟動上市,包括配置所有適當的前線團隊。
Additionally, we've invested and built out what we believe are really best-in-class patient access and support services to help patients get on the medicine both get on and be able to stay on. And then we're continuing to evaluate the best way to make sure that both the clinicians, all the appropriate healthcare providers and patients are aware of this important offering, so probably more to come on that, but please know that we're investing to win in this area.
此外,我們已投資並建置我們認為真正同級最佳的病患就醫可近性與支持服務,協助病患開始使用藥物,並且能夠持續用藥。接著,我們也持續評估最佳方式,確保臨床醫師、所有適當的醫療照護提供者以及病患都了解這項重要方案;因此後續可能還會有更多更新,但請放心,我們正在投入資源,力求在這個領域勝出。
Operator
Operator
Joanne Wuensch, Citibank.
Joanne Wuensch,花旗銀行。
Joanne Wuensch - Analyst
Joanne Wuensch - Analyst
Very nice start to the year. I'm going to pause for a moment on the ophthalmology franchise, in particular, your views on the US surgical and US contact lens market. I'm curious in particular about the almost 3% decline in the US Surgical in the quarter and how to think about that recovery throughout the remainder of the year?
今年開局非常不錯。我想先暫停一下,談談眼科事業,特別是你們對美國手術市場與美國隱形眼鏡市場的看法。我尤其好奇本季美國手術業務接近 3% 的下滑,以及該如何看待今年剩餘期間的復甦走勢?
Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech
Tim Schmid - Executive Vice President, Worldwide Chairman of MedTech
Joanne, thank you for the question. Vision overall, delivered a solid first quarter with sales growth of 3.6%, which is really consistent with our expectations. You will recall that business tends to be slower in the first couple of quarters and then accelerate throughout the year. We've seen that over the last couple and certainly, 2025 was no exception. Keep in mind that Q1 is typically our lowest quarter, and we're confident that we will see acceleration through the remainder of the year.
Joanne,謝謝你的提問。整體視力(Vision)業務第一季表現穩健,銷售成長 3.6%,這與我們的預期相當一致。你會記得,這項業務在前兩季通常較慢,之後會在全年逐步加速。過去幾年我們都看到這種情況,當然 2025 年也不例外。請記住,第一季通常是我們全年最低的一季,我們有信心在今年剩餘期間會看到加速成長。
If you break it down into the two component businesses, contact lens grew 2.7%, driven by the ACUVUE OASYS 1-day family. And especially, as you heard earlier from Joaquin, the MAX multifocal products, and these latest launches really complete our family of daily disposables and are solidifying our leadership in the category with exceptional comfort, clarity and stability. And when I look to Surgical Vision, we grew 6%, driven by normal seasonality.
若拆分為兩個組成業務,隱形眼鏡成長 2.7%,主要由 ACUVUE OASYS 1-day 系列帶動。尤其如你先前聽 Joaquin 提到的 MAX 多焦點產品,這些最新上市產品真正補齊了我們日拋產品家族,並以卓越的舒適度、清晰度與穩定性,鞏固我們在該類別的領導地位。至於手術視力(Surgical Vision),我們成長 6%,主要受正常季節性因素帶動。
We continue to see strong global momentum in premium IOLs led by TECNIS Odyssey and PureSee where we're outpacing the market globally, and this premium segment remains a key driver of value and differentiation. I think to your pointed question on US performance, if we look at Surgical Vision growth in the quarter, it was offset in the US due to competitive pressures as new entrants came into the market, which is not unexpected given the fierce stature of this portfolio. We also continue to expect some seasonality in our business as growth won't always be linear. That said, we remain confident in our clinical position with TECNIS Odyssey.
我們持續看到高階人工水晶體(premium IOL)在全球的強勁動能,由 TECNIS Odyssey 與 PureSee 領軍,我們在全球的表現優於市場,而這個高階區隔仍是價值與差異化的關鍵驅動因素。針對你所聚焦的美國表現,如果看本季手術視力的成長,美國因競爭壓力而被抵銷,原因是有新進入者進入市場;考量到這個產品組合的強勢地位,這並不令人意外。我們也仍預期業務會有一定季節性,成長不會總是線性。即便如此,我們對 TECNIS Odyssey 的臨床定位仍然充滿信心。
And as we prepare for the launch of TECNIS PureSee in the US later this year. And we have seen extremely strong uptake of TECNIS PureSee globally, nearly half -- it's actually almost 0.5 million eyes worldwide have already experienced a clearer uninterrupted vision with this premium IOL and TECNIS PureSee, which received FDA approval, this quarter is the first and only US FDA-approved extended depth of focus IOL with no warning on loss of contrast sensitivity, which is a huge game changer for physicians and the comfort they have in recommending an IOL.
同時,我們也在為今年稍晚 TECNIS PureSee 於美國上市做準備。我們已看到 TECNIS PureSee 在全球的採用極為強勁,全球已有將近一半——實際上接近 50 萬隻眼——透過這款高階 IOL 體驗到更清晰、不中斷的視覺;而 TECNIS PureSee 本季獲得 FDA 核准,是美國 FDA 首款且目前唯一一款「延伸景深」IOL,且在「對比敏感度下降」方面沒有警語,這對醫師以及他們在推薦 IOL 時的信心而言,是一個巨大的改變。
In fact, 97% of patients reported no bothersome visual disturbances like halos or glares, which can often occur with other IOLs and we're really excited about the launch of PureSee here in the US, which will give surgeons an important new lens option for their patients. And as we continue to focus on the premiumization of our portfolio, we firmly believe that the combination of TECNIS Odyssey, which is in the market and now TECNIS PureSee will be a key driver of value and differentiation. On the back of this, we can confidently say that we expect accelerated growth in the back half of the year for our Surgical Vision business and Vision overall, including here in the US. So thank you again for the question.
事實上,97% 的病患回報沒有令人困擾的視覺干擾,例如光暈或眩光;這些情況在其他 IOL 上往往較常見。我們對 PureSee 在美國的上市感到非常振奮,這將為外科醫師提供一個重要的新鏡片選擇,造福其病患。隨著我們持續推動產品組合高階化,我們堅信已在市場上的 TECNIS Odyssey,加上即將推出的 TECNIS PureSee,將成為價值與差異化的關鍵驅動。基於此,我們可以有信心地表示:我們預期手術視力業務以及整體視力業務在今年下半年將加速成長,包括在美國市場也是如此。再次感謝你的提問。
Operator
Operator
David Risinger, Leerink Partners.
David Risinger,Leerink Partners。
David Risinger - Analyst
David Risinger - Analyst
So my question is on JNJ-4804 the coantibody. Could you talk about your vision for its role in IBD treatment paradigms and the readouts that we should be focused on? And then since others have asked multiple questions. Joe, could you just share the IMAAVY sales like you did in the first quarter for INLEXZO?
我的問題是關於 JNJ-4804 這個共抗體(coantibody)。你能談談你們對它在 IBD 治療策略中的角色願景,以及我們應該關注哪些讀出(readouts)嗎?另外,既然其他人已經問了多個問題。Joe,你能否像第一季分享 INLEXZO 一樣,分享一下 IMAAVY 的銷售額?
John Reed - Executive Vice President - Pharmaceuticals, R&D
John Reed - Executive Vice President - Pharmaceuticals, R&D
Yes. Thanks for the question about 4804. So just to remind the audience, this is our coantibody therapeutic that combines guselkumab, our IL-23 inhibitor, also known as TREMFYA together with our TNF inhibitor, golimumab and we are in a position to potentially be the first with a coantibody therapeutic in the IBD space.
好的。謝謝你關於 4804 的問題。先提醒各位,這是我們的共抗體治療,將 guselkumab(我們的 IL-23 抑制劑,也就是 TREMFYA)與我們的 TNF 抑制劑 golimumab 結合在一起;我們有機會成為 IBD 領域首個推出共抗體治療的公司。
Now, even with the best of therapies, more than half of patients with IBD do not achieve a complete remission, and so we see for patients where monotherapy is not getting the job done to then offer this dual therapy, the combined therapy is a fixed dose combination.
即使在最好的治療下,仍有超過一半的 IBD 病患無法達到完全緩解;因此,對於單一療法無法達標的病患,我們認為可提供這種雙重療法。這種合併治療為固定劑量複方。
So the Phase 2 data on that in both Crohn's and Colitis, there were two separate studies will be presented in the coming year at a medical conference, so you'll have an opportunity to see the details of the data there, and that will provide more insights into the specifics around the most ideal patient populations for this kind of co-antibody therapeutic.
關於克隆氏症與結腸炎的第二期(Phase 2)數據,分別來自兩項獨立研究,將在未來一年於醫學會議上發表,因此你將有機會在那裡看到數據細節;這也會讓大家更深入了解,哪些病患族群最適合這類共抗體治療。
But we're really excited to move this forward now with pace. The Phase 3 programs are underway and really excited to then try to break through these efficacy ceilings that have limited how many of these patients who battle with inflammatory bowel disease are able to achieve a complete remission and really get that mucosal healing from their therapy.
不過,我們對於以更快速度推進此項目感到非常興奮。第三期(Phase 3)計畫已在進行中;我們也非常期待能突破目前療效天花板的限制,讓更多與發炎性腸道疾病奮戰的病患得以達到完全緩解,並真正從治療中獲得黏膜癒合。
Darren Snellgrove - Vice President - Investor Relations
Darren Snellgrove - Vice President - Investor Relations
David, thanks for the extra question there. We actually don't disclose the IMAAVY sales at this point in time. So more to come on that. We actually have time for one last question.
David,謝謝你額外的問題。我們目前不揭露 IMAAVY 的銷售額。所以後續會再更新。我們其實還有時間再問最後一個問題。
Operator
Operator
Matt Miksic, Barclays.
Matt Miksic,巴克萊。
Matthew Miksic - Analyst
Matthew Miksic - Analyst
Great. And congrats again on a really impressive quarter and start to the year. So you mentioned INLEXZO a couple of times, and I know you've talked at length about it in the past. Just wondering if you could give us a sense of what the commercialization plan and rollout looks like for that, given it's a slightly different delivery mechanism than many of your other therapeutics and kind of where you are with that? Any metrics you can provide would be great. And thanks again.
很好。也再次恭喜你們交出非常亮眼的一季表現與年度開局。你們提到 INLEXZO 幾次,我也知道你們過去已經詳細談過。我想請教,考量它的給藥機制與你們其他許多治療產品略有不同,你們能否讓我們了解其商業化計畫與推廣(rollout)會是什麼樣子,以及目前進展到哪個階段?若能提供任何指標(metrics)會很有幫助。再次感謝。
Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals
Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals
Sure. So maybe as a reminder, despite recent advances in bladder cancer, unmet need in that area really remains significant and this is for bladder sparing options. There's almost 600,000 new patients diagnosed each year and another 400,000 that are recurring, so really, really big market opportunity.
當然。也許先提醒一下,儘管膀胱癌近年有所進展,但該領域的未滿足需求仍然相當顯著,特別是在保留膀胱(bladder sparing)的治療選項方面。每年約有將近 60 萬名新診斷病患,另有 40 萬名復發病患,因此這確實是一個非常、非常大的市場機會。
We've launched INLEXZO into the BCG unresponsive population and are really excited to be able to move forward in the coming years and to be able to broaden that population. As a reminder, we really designed the product to fit seamlessly into urology practice so that, relatively speaking, easy to insert and to retrieve and fits very, very nicely into practice.
我們已將 INLEXZO 推向 BCG 無反應族群,並且非常振奮能在未來幾年持續推進,並進一步擴大該族群。提醒一下,我們在設計這項產品時,確保能無縫融入泌尿科臨床實務,因此相對而言,容易置入與取出,並且非常、非常契合臨床作業流程。
So how is the product doing? So INLEXZO's outperforming all the recent launches in the non-muscle invasive bladder cancer space. And that's based on kind of the unique patients that were treated in our first six months post approval. One in five eligible patients are starting on an INLEXZO regimen during the first quarter.
那麼這項產品表現如何?INLEXZO 的表現優於近期所有在非肌肉侵襲性膀胱癌領域的新上市產品。這是基於我們在核准後前六個月所治療的、具一定獨特性的患者族群。在第一季,五分之一符合資格的患者開始採用 INLEXZO 治療方案。
And then what I think you really want to know is following our J-code approval which came at the beginning of April. What we saw in the first week was actually a over 50% increase in new patient insertions and the second week that we have under our belt, we actually saw that jump up to almost 90% increase in new patient insertion. So consistent with what we've articulated on our expectations for this product once there's certainty on reimbursement following the J-code, we're seeing play out in practice so far in the first couple of weeks. So very, very excited in that -- in the BCG unresponsive space and look to broaden that into broader populations
接著,我想你們真正想知道的是,在我們於四月初取得 J-code 核准之後的情況。我們在第一週看到新患者置入量實際增加超過 50%,而在我們已掌握的第二週,新患者置入量的增幅更跳升至接近 90%。因此,這與我們先前所闡述的預期一致:一旦在 J-code 之後報銷具備確定性,我們預期這項產品的表現將會提升;而目前在前幾週的實務中正如預期地展現出來。所以我們對於——在 BCG 無反應領域——感到非常、非常振奮,並期待將其擴展到更廣泛的族群。
John Reed - Executive Vice President - Pharmaceuticals, R&D
John Reed - Executive Vice President - Pharmaceuticals, R&D
Yes. Just to remind with INLEXZO, we achieved the highest complete response rates ever seen for a therapy for non-muscle invasive bladder cancer achieved breakthrough designation from the FDA as well as the rapid review from FDA and in Japan, the PDMA accepted our submission based on the single-arm data, they've never previously accepted a submission based on single arm data just showing how exciting these data are and how much unmet need there is.
是的。再提醒一下,INLEXZO 取得了迄今在非肌肉侵襲性膀胱癌治療中所見的最高完全反應率,並獲得 FDA 的突破性療法認定以及 FDA 的快速審查;在日本方面,PMDA 也基於單臂資料受理了我們的申請——他們過去從未基於單臂資料受理申請——這充分顯示這些數據有多令人振奮,以及未被滿足的醫療需求有多大。
I would also draw your attention to INLEXZO is just the beginning. Right behind that, we have the ERDA, intravascular drug-releasing system, this has erdafitinib. That is a small molecule targeted therapy that addresses the intermediate risk non-muscle invasive bladder cancer population. There, we achieved in the biomarker-defined population, complete response rates north of 90%. And that device also custom designed to deliver that payload delivers medicine for three months compared to INLEXZO, which is three weeks. So we just keep getting better and better as we do the next iteration, the next iteration around this intravascular drug-releasing system.
我也想提醒各位注意,INLEXZO 只是開始。緊接在後的是 ERDA——血管內藥物釋放系統——其中包含 erdafitinib。這是一種小分子標靶治療,針對中度風險的非肌肉侵襲性膀胱癌族群。在該生物標記物界定的族群中,我們達到超過 90% 的完全反應率。而該裝置也為了遞送該有效載荷而量身設計,可持續釋放藥物三個月;相較之下,INLEXZO 為三週。因此,隨著我們在這套血管內藥物釋放系統上進行下一次、再下一次的迭代,我們只會越做越好。
Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals
Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals
And then in terms of our go-to-market model, this really represents the best of Johnson & Johnson and something that only a company like Johnson & Johnson with both an Innovative Medicine and a MedTech business. can do and bring to market. So in addition to the product that we've developed and the reimbursement and access support and that the sort of excellence that's coming out of the Innovative Medicine business, we've really been able to tap into MedTech and their world-class training institutes, their modular training that can literally go to the site of care. And so we're deploying that throughout the United States to make sure that urologists and their practices are up to speed on INLEXZO and fully trained to begin insertion for their patients as they deem fit. So really bringing the best of Johnson & Johnson to bear for this product.
接著就我們的上市推廣(go-to-market)模式而言,這確實體現了強生(Johnson & Johnson)的精華,也只有像強生這樣同時擁有創新醫藥(Innovative Medicine)與醫療科技(MedTech)業務的公司,才能做到並將其推向市場。因此,除了我們所開發的產品,以及來自創新醫藥業務的報銷與可近性支援、以及那種卓越能力之外,我們也確實能夠運用 MedTech 的資源,包括其世界級訓練機構與可模組化的訓練,甚至可以直接到照護現場進行。因此,我們正在全美部署這些資源,確保泌尿科醫師及其診所對 INLEXZO 充分掌握,並完成完整訓練,以便在其認為合適時,開始為患者進行置入。因此,這真的是把強生最好的能力都用在這項產品上。
Darren Snellgrove - Vice President - Investor Relations
Darren Snellgrove - Vice President - Investor Relations
Great. Okay. Thanks, Matt, and thanks to everyone for your questions and your continued interest in our company. I'll now turn the call over to Joaquin for some brief closing remarks.
很好。好的。謝謝你,Matt,也謝謝各位的提問以及對我們公司的持續關注。我現在把電話交給 Joaquin,請他做一些簡短的結語。
Joaquin Duato - Chairman of the Board, Chief Executive Officer
Joaquin Duato - Chairman of the Board, Chief Executive Officer
Thank you, everybody, for joining us today. As you have heard, Johnson & Johnson has the strongest portfolio and pipeline in our history, and we are relentlessly focused on innovation that is delivering real impact for patients. With our Q1 performance, we are off to a strong start, reinforcing our confidence in the year ahead and our ability to raise the standard of care in our six key focus areas.
謝謝大家今天加入我們。如各位所聽到的,強生(Johnson & Johnson)擁有我們歷史上最強的產品組合與研發管線,我們持續不懈地聚焦於創新,為患者帶來真正的影響。憑藉我們第一季(Q1)的表現,我們已強勢開局,進一步強化我們對未來一年的信心,以及我們在六大重點領域提升照護標準的能力。
Thank you for your interest in Johnson & Johnson. We'll see you at our EBR late December, too, to give you more details on these new products that you were asking, and enjoy the rest of your day.
感謝您對強生(Johnson & Johnson)的關注。我們將在 12 月下旬的 EBR 與各位見面,屆時會就您所詢問的這些新產品提供更多細節,也祝您今天剩下的時間愉快。
Operator
Operator
Thank you. This concludes today's Johnson & Johnson's first-quarter 2026 earnings conference call. You may now disconnect.
謝謝。以上為強生(Johnson & Johnson)2026 年第一季財報電話會議的全部內容。您現在可以掛線。